Patient Reported Outcome study of Dapagliflozin on glycemic control and treatment satisfaction in overweight patients with type 2 diabetes mellitus - PRO study

Japan society for Patient Reported Outcome0 个研究点目标入组 220 人开始时间: 2015年1月23日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients who meet any of the following criteria are excluded from the study subjects. 1. A patient who is not using an antidiabetic drug at the time of consenting 2. A patient with a history of severe hypoglycemia within a year 3. A patient with type 1 diabetes mellitus or secondary diabetes mellitus 4. A patient with severe infection, a pre or postsurgical patient, and a patient with serious trauma 5. A patient with a history of MI (myocardial infarction), AP (angina), or CI (cerebral infarction) 6. A patient with atrial fibrillation or frequent ventricular premature contraction 7. A patient with moderate or severe heart failure (a patient at stage 3 or a higher stage of the NYHA/New York Heart Association classification) 8. A patient with moderate renal dysfunction (serum creatinine in mg/dL: male, 1.4 < female, 1.2 <) 9. A patient with severe liver dysfunction (AST 100 IU/l or higher) 10. A patient with ascites retention, and a patient with a brain disorder 11. A patient with unstable hypertension or unstable dyslipidemia within 12 weeks before consenting 12. A patient with alcohol or drug dependence 13. A patient who is pregnant or breast-feeding, suspected of being pregnant, or has a plan to get pregnant 14. A patient with dementia 15. A patient who meets a contraindication of the study drug 16. A patient who is using insulin and GLP-1, and a patient who is routinely using injectors 17.A patient conditions deemed inappropriate by an investigator in charge

发起方

Japan society for Patient Reported Outcome